TC BioPharm is at the forefront of developing innovative cancer and infectious disease treatments through its pioneering allogeneic gamma delta T cell therapy platform. This technology is notable for being the first scalable "off the shelf" solution, which allows for broader accessibility and application in treating various cancers. The platform is designed to minimize side effects and eliminate off-tumor toxicity, making it a safer alternative for patients. The company emphasizes a streamlined approach to manufacturing and logistics, ensuring that their therapies can be produced efficiently and delivered to patients in a timely manner.

The company maintains rigorous control over the critical elements of drug development, with a dedicated team of interdisciplinary scientists working in a state-of-the-art research facility in the UK. Their operations include GMP (Good Manufacturing Practice) compliant cell and gene manufacturing suites, which are essential for producing high-quality therapeutic products. Additionally, TC BioPharm's clinical development team collaborates closely with physicians and hospitals globally, facilitating the translation of their research into practical treatments for patients. This integrated model underscores their commitment to advancing medicine and improving patient outcomes through innovative therapies.

United Kingdom

TC BioPharm is a publicly traded, clinical-stage cell therapy company developing advanced allogeneic CAR-T cell therapy products for the treatment of cancer, as well as developing gamma delta T cell therapies for the treatment of infectious disease.

We have a growing team based in our Glasgow office, alongside a wide range of scientific advisors, and partner organisations.

TC BioPharm

Company Details